In unresectable Stage 3 NSCLC advances in techniques and technology have improved concurrent chemoradiotherapy1-3

Modern Radiation Techniques May Improve Therapy in Challenging Stage 3 NSCLC Cases

…I want to emphasize that it’s very rare that we have a patient that’s not treatable with modern-day techniques.

–Dr Kristin Higgins*

Advances in Techniques and Technologies Have Improved the Quality of Radiation Therapy Given as a Part of CRT, Allowing for Reductions in Toxicity and Potentially Help With Preservation of Patient Performance Status1-4

Advances in planning techniques

3D CT-based simulation

3D CT-based simulation for radiation treatment planning has been one of the most important technological advances in radiation oncology, and allows for better anatomic definition of target lesions1

Use of 3D CT-based simulation has also been shown to improve survival outcomes vs conventional simulations1

Advances in radiation therapy technology


IMRT is an advanced form of radiotherapy that allows radiation oncologists to sculpt radiation intensity in complex ways, allowing for high-dose volumes around the site of disease and sparing adjacent organs at risk2

Use of IMRT allows for consistent or, in select patients, improved radiation efficacy with decreases in toxicity2,3

Advances in Radiation Technology May Improve Concurrent CRT in Unresectable Stage 3 NSCLC

We can now treat people with CRT that we couldn’t 10 years ago, and we can treat them with less toxicity.

–Dr Roy Decker*

NSCLC=non-small cell lung cancer; CRT=chemoradiotherapy; 3D CT=3-dimensional computed tomography; IMRT=intensity-modulated radiation therapy; AE=adverse event.

*The views and opinions expressed in the Art of CRT video series are those of the individual panel members and do not represent the views or opinions of AstraZeneca. These videos contain anecdotal information gathered from a discussion with 8 physicians and nurses based on their opinions/experiences. Recommendations are general and may vary with patients.

References: 1. Chen AB, Neville BA, Sher DJ, Chen K, Schrag D. Survival outcomes after radiation therapy for stage III non–small-cell lung cancer adoption of computed tomography–based simulation. J Clin Oncol. 2011;29:2305-2311. 2. Chan C, Lang S, Rowbottom C, Guckenberger M, Faivre-Finn C; IASLC Advanced Radiation Technology Committee. Intensity-modulated radiotherapy for lung cancer: current status and future developments. J Thorac Oncol. 2014;9(11):1598-1608. 3. Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non–small-cell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56-62. 4. Poirier P. Factors affecting performance of usual activities during radiation therapy. Oncol Nurs Forum. 2007;34(4):827-834.